LeMaitre Vascular Inc. (LMAT) Company Profile
LeMaitre Vascular, Inc. develops, manufactures, and markets vascular devices for the treatment of peripheral vascular disease worldwide. The company provides vascular products, including balloon catheters for the removal of blood clots, occlusion, and facilitation of blood flow; carotid shunts for the facilitation of blood flow to brain during carotid plaque removal; remote endarterectomy devices for the removal of blockages in the major arteries of the leg; and valvulotomes for the destruction of vein valves to create vein bypass grafts. Its vascular products also consist of vascular grafts, which are synthetic vessels for use in bypass and replacement procedures; vascular patches that are synthetic and biological patches for use in closing incisions in a blood vessel; vein strippers for single-incision removal of varicose veins; and vessel closure systems for the attachment of blood vessels, primarily for dialysis access. In addition, the company offers endovascular prod ucts comprising aortic stent grafts for endovascular repair of abdominal and thoracic aortic aneurysms, and thoracic dissections; manual contrast injectors for the injection of contrast media into blood vessels; modeling catheters for the improvement in the seal of aortic stent grafts; and radiopaque tapes for the improvement in precision of vascular and endovascular procedures. Further, it provides general surgery products, such as laparoscopic cholecystectomy devices for introducing dye into the cystic duct. Additionally, the company distributes Powerlink System, a bifurcated abdominal stent graft; and ArterX Vascular Sealant, a surgical sealant, as well as engages in private label manufacturing. It sells its products through direct and indirect sales forces, and a network of distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burli ngton, Massachusetts.
News about LMAT
Zacks: Brokerages Expect Pulmatrix Inc (PULM) to Announce -$0.14 Earnings Per Share
Analysts forecast that Pulmatrix Inc (NASDAQ:PULM) will announce earnings per share of ($0.14) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Pulmatrix’s earnings. The highest EPS estimate is...Read More>>>
Buy Netflix (NFLX) Stock On the Dip Before Q3 Earnings?
Netflix (NFLX ) stock has suffered since its now infamous Q2 subscriber miss. But the streaming TV giant’s growth prospects look strong as it continues to bulk up on content, which includes a new movie starring global superstar Dwayne “T...Read More>>>
Better Buy: Momo Inc. vs. Match Inc
Online dating has been a mixed blessing for relationship-seeking singles, but it's been a big winner for investors. Shares of China's Momo (NASDAQ:MOMO) have raced 79% so far this year, up a juicy 138% since the start of last year. Tinder parent Ma...Read More>>>
LeMaitre Vascular Inc (LMAT) Expected to Post Earnings of $0.21 Per Share
Equities research analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will post $0.21 earnings per share for the current quarter, Zacks reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings. The highest EPS est...Read More>>>
Polaris Venture Management Co. V, L.L.C. Buys Neuronetics Inc, Pulmatrix Inc
Waltham, MA, based Investment company Polaris Venture Management Co. V, L.L.C. buys Neuronetics Inc, Pulmatrix Inc during the 3-months ended 2018-06-30, according to the most recent filings of the investment company, Polaris Venture Management Co. V,...Read More>>>